VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 40 filers reported holding VERONA PHARMA PLC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $8,074,190 | -87.1% | 381,939 | -87.8% | 1.14% | -89.5% |
| Q1 2023 | $62,798,774 | -16.4% | 3,127,429 | +8.8% | 10.80% | -9.4% |
| Q4 2022 | $75,137,494 | +174.4% | 2,875,526 | +7.3% | 11.92% | +147.7% |
| Q3 2022 | $27,379,000 | +605.3% | 2,678,982 | +189.1% | 4.81% | +442.0% |
| Q2 2022 | $3,882,000 | -16.0% | 926,602 | 0.0% | 0.89% | -18.8% |
| Q1 2022 | $4,624,000 | -25.7% | 926,602 | 0.0% | 1.09% | -46.8% |
| Q4 2021 | $6,227,000 | +22.6% | 926,602 | 0.0% | 2.05% | +11.2% |
| Q3 2021 | $5,078,000 | +825.0% | 926,602 | +1003.8% | 1.85% | +717.3% |
| Q2 2021 | $549,000 | -21.8% | 83,944 | 0.0% | 0.23% | -23.6% |
| Q1 2021 | $702,000 | +0.3% | 83,944 | -16.1% | 0.30% | +18.4% |
| Q4 2020 | $700,000 | +12.2% | 100,000 | 0.0% | 0.25% | -5.3% |
| Q3 2020 | $624,000 | – | 100,000 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,111,112 | $11,356,000 | 29.98% |
| Aisling Capital Management LP | 1,332,485 | $13,618,000 | 9.04% |
| Abingworth LLP | 2,457,500 | $25,091,000 | 8.58% |
| Fairmount Funds Management LLC | 2,678,982 | $27,379,000 | 4.81% |
| Vivo Capital, LLC | 4,249,918 | $43,434,000 | 4.80% |
| NEA Management Company, LLC | 5,584,753 | $57,076,000 | 2.85% |
| Octagon Capital Advisors LP | 1,324,868 | $13,540,000 | 2.34% |
| Samsara BioCapital, LLC | 938,890 | $9,595,000 | 2.24% |
| ACT CAPITAL MANAGEMENT, LLC | 143,500 | $1,467,000 | 2.02% |
| Frazier Life Sciences Management, L.P. | 2,099,541 | $21,457,000 | 1.65% |